National Research Corporation (NASDAQ:NRC), the experience-improvement firm known as NRC Health, reported fourth-quarter results that signaled a steady operational turnaround, bolstered by a fifth consecutive quarter of growth in its core recurring contract base.
The Lincoln, Nebraska-based company saw total revenue rise to $35.2 million for the period ended December 31, 2025, a 2% increase over the third quarter.
While the healthcare technology sector has faced tightening hospital budgets, NRC Health’s Total Recurring Contract Value (TRCV) grew 8% year-over-year to $144.1 million, providing a predictable floor for 2026 earnings.
Under the leadership of CEO Trent Green, who took the helm in mid-2025, the company has pivoted from aggressive cost-cutting to a growth-oriented strategy focused on "Human Understanding®" and AI-driven insights.
This shift was evident in the quarter’s 25% adjusted EBITDA margin, reflecting a balance between reinvestment in its "Huey" AI engine and disciplined operational spend.
On the capital allocation front, the Board of Directors declared a quarterly dividend of $0.16 per share, payable on April 10, 2026.
The company also remains active in its share repurchase program, continuing to return value to shareholders amid its strategic transition.